40 likes | 61 Views
Based on years of abundant experience in IVD (in vitro diagnostics) antibodies development, Creative Biolabs provides a variety of high quality IVD antibodies custom development service against NT-proBNP marker for diagnosis of heart failure (HF). With our professional scientists, we are confident in satisfying every customer's requirement.
E N D
IVD Antibodies for NT-proBNP Marker Based on years of abundant experience in IVD (in vitro diagnostics) antibodies development, Creative Biolabs provides a variety of high quality IVD antibodies custom development service against NT-proBNP marker for diagnosis of heart failure (HF). With our professional scientists, we are confident in satisfying every customer's requirement. ProBNP is a 108-amino acid precursor peptide of the BNP (B-type natriuretic peptide) which is a 32-amino acid protein secreted from cardiac ventricles. On account of the enhanced wall tension in ventricles, ProBNP is catalyzed by a protease resulting in the inactive form of a 76 amino acids N-terminal-proBNP (NT-proBNP) and the biologically active form of BNP. Contrast to BNP, NT- proBNP owns a longer half-life and is not influenced by the management of exogenous BNP. It more relies on renal elimination and the half-life estimated is about 2 hours. NT-proBNP has been studied for diagnosis of HF and left ventricular systolic dysfunction (LVSD). It has been accepted by the HF classification of New York Heart Association that NT-proBNP levels were consistent with the clinical severity of the disease. Figure 1. Schematic representation of proBNP processing and cross-reactivity of assays
measuring BNP and NT-proBNP. ProBNP can be posttranslationally O-glycosylated (O- glyc) within the Golgi apparatus. Both O-glycosylated and non-O-glycosylated proBNP are cleaved to BNP and NT-proBNP in equimolar fashion by the enzyme furin and then secreted into the circulation. (Gruden, G. 2014) NT-proBNP Marker of Heart Failure HF usually can be mixed up with other situations, and it may co-exist with them. Markers are helpful in diagnosis, treatment monitoring and to inform prognosis. NT-proBNP is a superior marker for HF and it enables to be used together with other cardiac biomarker tests to measure heart stress and damage. It has been proven that increased NT-proBNP levels are invariably connected with raised mortality in patients with HF. There are several analytical advantages of NT- proBNP as a diagnostic marker of HF. Firstly, NT-proBNP is highly stable both in vivo and in vitro and NT-proBNP tests are matched to an ordinary standard and prove much less method variation than that of BNP approaches. Furthermore, the results seen with NT-proBNP will be about 8-10 times higher than those commonly seen, on account of their higher molecular weight and the strong in vivo stability.
Figure 2. Plasma Levels of proBNP, total BNP, and NT-proBNP in normal and heart failure. Bar graph showing the total BNP, proBNP (A) and NT-proBNP (B) levels in healthy subjects and heart failure patients with NYHA classes 1–2 and 3–4. (Nishikimi, T. 2013) NT-proBNP Marker Antibodies IVD quickly becomes pivotal to the delivery of healthcare. IVD Antibodies are broadly applied for immunology methods of IVD, which is developed to contribute to diagnosis of disease or other conditions and play an important role in prevention, monitoring and treatment. IVD antibodies for NT-proBNP help the characterization and quantification of NT-proBNP in cells, tissues or other
biological samples. Creative Biolabs provides high quality IVD antibodies against NT-proBNP for your research or clinic needs. Our various high-affinity IVD antibody development services against NT- proBNP marker will contribute greatly to the success of your projects. Creative Biolabsalso provides other IVD antibodies. Please feel free to contact us for more information and a detailed quote. Reference 1. Taylor, C. J. (2014). “The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis”.BMJ open 4(4), e004675. 2. Nishikimi, T. (2013). “Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure”.PloS one 8(1), e53233. 3. Gruden, G. (2014). “Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research”. Diabetes Care 37(11), 2899- 2908. Related Services: IVD Antibody Development Services for BNP Marker IVD Antibodies for MR-proANP IVD Antibody Development Services for ST2 IVD Antibodies for GDF-15 IVD Antibodies for CD154 Marker